BioLine RX Valuation
| BLRX Stock | ILS 8.10 0.10 1.25% |
At this time, the firm appears to be overvalued. BioLine RX shows a prevailing Real Value of S7.68 per share. The current price of the firm is S8.1. Our model approximates the value of BioLine RX from analyzing the firm fundamentals such as Shares Owned By Insiders of 0.25 %, return on equity of -0.37, and Current Valuation of (13.02 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that BioLine RX's price fluctuation is moderately volatile at this time. Calculation of the real value of BioLine RX is based on 3 months time horizon. Increasing BioLine RX's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioLine RX is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioLine Stock. However, BioLine RX's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.1 | Real 7.68 | Hype 8.0 | Naive 7.04 |
The real value of BioLine Stock, also known as its intrinsic value, is the underlying worth of BioLine RX Company, which is reflected in its stock price. It is based on BioLine RX's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioLine RX's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BioLine RX helps investors to forecast how BioLine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioLine RX more accurately as focusing exclusively on BioLine RX's fundamentals will not take into account other important factors: BioLine RX Total Value Analysis
BioLine RX is currently forecasted to have takeover price of (13.02 M) with market capitalization of 135.72 M, debt of 10.69 M, and cash on hands of 40.61 M. The negative valuation of BioLine RX may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the BioLine RX fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(13.02 M) | 135.72 M | 10.69 M | 40.61 M |
BioLine RX Asset Utilization
One of the ways to look at asset utilization of BioLine is to check how much profit was generated for every dollar of assets it reports. BioLine RX shows a negative utilization of assets of -0.2 percent, losing S0.002029 for each shekel of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each shekel of assets it shows. Put another way, asset utilization of BioLine RX shows how discouraging it operates for each shekel spent on its assets.BioLine RX Ownership Allocation
BioLine RX holds a total of 922.87 Million outstanding shares. Almost 99.65 percent of BioLine RX outstanding shares are held by general public with 0.25 (percent) owned by insiders and only 0.1 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.BioLine RX Profitability Analysis
Net Loss for the year was (27.05 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BioLine RX's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BioLine RX and how it compares across the competition.
About BioLine RX Valuation
The stock valuation mechanism determines BioLine RX's current worth on a weekly basis. Our valuation model uses a comparative analysis of BioLine RX. We calculate exposure to BioLine RX's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioLine RX's related companies.BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.
8 Steps to conduct BioLine RX's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BioLine RX's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BioLine RX's valuation analysis, follow these 8 steps:- Gather financial information: Obtain BioLine RX's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BioLine RX's revenue streams: Identify BioLine RX's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BioLine RX's industry and market trends, including the size of the market, growth rate, and competition.
- Establish BioLine RX's growth potential: Evaluate BioLine RX's management, business model, and growth potential.
- Determine BioLine RX's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BioLine RX's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |